Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 7, 2026Diabetes

2037-P: Diabetes-Related Clinical Quality Performance of Value-Based Payment Models for Medicare Advantage Members

View Full Paper
Ask AI
Bookmark
Share

Authors

EBEleanor M. BeltzXWXin WeiAZAmanda Zaleski

Discussion

Loading...

Member takes

Overview

Retrospective cohort study compares diabetes-related quality in value-based versus non-value-based models, suggesting benefits of risk sharing.

Key Points

  • The study aimed to compare diabetes-related clinical quality between value-based payment models and non-value-based payment models in Medicare Advantage.
  • Retrospective cohort study evaluating clinical quality scores in relation to payment models and risk sharing levels.
  • Outcome measures included statin use in persons with diabetes, medication adherence, and blood sugar control.
  • Analyses utilized generalized linear models with Bonferroni correction and post-hoc Tukey tests.
  • VBP models outperformed non-VBP models by +1.7% for statin use and medication adherence and +24.1% for blood sugar control (all P<.001).
  • Two-sided risk sharing outperformed one-sided risk and pay-for-performance for both statin use and medication adherence (P<.001).
  • Blood sugar control scores improved along with risk sharing, from +3.3% to +15.4% as risk sharing increased (all P<.001).

Cite This Study

Beltz et al. (2026) studied this question.

synapsesocial.com/papers/6a250be87def13d035e1bdc3https://doi.org/10.2337/db26-2037-p
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The impact of transition strategies from fee-for-service to value-based payment models on quality of care, patient outcomes, and healthcare costs: A systematic analysis2025
  2. 2Clinical Quality Performance of Value-Based and Fee-for-Service Models for Medicare Advantage2025
  3. 3Acute Diabetes Complications After Transition to a Value-Based Medication Benefit2024 · 5 citations
  4. 4Treatment approaches and costs associated with diabetes clinical metrics as measured by Healthcare Effectiveness Data and Information Set (HEDIS)2024 · 2 citations
  5. 51180-OR: Health Effects of Two Strategies to Enhance Health Care Affordability: Medication-Targeted vs. Broad Out-of-Pocket Cost Reductions2026